Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06458439 · ClinicalTrials.gov registry record · Phase 2
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
A Phase 2 study of Lymphoma, Non-Hodgkin and Refractory Diffuse Large B-Cell Lymphoma, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT06458439: Recruiting Phase 2 study of Lymphoma, Non-Hodgkin and Refractory Diffuse Large B-Cell Lymphoma, sponsored by Abramson Cancer Center at Penn Medicine.
NCT06458439 is a Phase 2 study of Lymphoma, Non-Hodgkin and Refractory Diffuse Large B-Cell Lymphoma that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 31 participants, below the 389-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06458439, a Phase 2 study of Lymphoma, Non-Hodgkin and Refractory Diffuse Large B-Cell Lymphoma, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.
Primary Outcome
Whether participants receive CAR T-cell infusion (yes/no)
Conditions Studied
Interventions
- DRUG Epcoritamab
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2024-09-24 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT06458439 shows while recruiting
NCT06458439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 389-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (92% lower).
The record links to 5 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which Epcoritamab is the first listed.
NCT06458439 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06458439 about?
NCT06458439 is a clinical study titled "Epcoritamab-CAR T Cells for Large B-cell Lymphomas". This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.
What is the current status of trial NCT06458439?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2024-09-24. Estimated completion is 2027-12.
What conditions does trial NCT06458439 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Refractory Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma, Relapsed Diffuse Large B-cell Lymphoma, Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma.
What interventions are being tested in trial NCT06458439?
The interventions under investigation include: Epcoritamab (DRUG).
Who is sponsoring clinical trial NCT06458439?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06458439 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06458439's enrollment target sits among peer trials
31 46th of 58 higher than 13 of 58 other Lymphoma, Non-Hodgkin trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, Non-Hodgkin trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RECRUITING · Phase 2
-
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
RECRUITING · Phase 2
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI